grish hcc presentation
DESCRIPTION
PPT2TRANSCRIPT
![Page 1: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/1.jpg)
HEPATOCELLULAR
CARCINOMAWE CAN CHANGE THE OUTCOME
![Page 2: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/2.jpg)
![Page 3: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/3.jpg)
Background
The incidence of hepatocellular carcinoma (HCC) has
continued to rise in recent years.
This increase has been attributed to alcohol-induced
liver diseases, metabolic syndrome, and the rising
number of hepatitis B and C viral infections.
Treatment options are evolving. With better
understanding of liver anatomy and physiology surgical
treatment emerges as the main curative option
![Page 4: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/4.jpg)
Case Discussion
68 years old male, Diabetic/ hypertensive/ IHD ( on medical
management)
RUQ discomfort - 2-3 months
generalized weakness, fatigue, exertional breathlessness
No addictions, No H/O hepatitis infection.
GPE - pallor ++, BMI-35, otherwise normal, good performance
status
Abdomen examination– unremarkable
![Page 5: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/5.jpg)
Investigations
Hb – 6.6 gm % - transfused 2 PRC’s.
PS –Normocytic hypochromic aneamia
Platelets-3.2 lakhs
INR-1.21
LFT bil-1.2,alb 3.3 OT/PT-56/67
Iron , B12 low
Viral markers negative
Echo, ECG - normal
![Page 6: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/6.jpg)
Investigations
UGI scopy – normal study of stomach
Colonoscopy – small Haemorrhoids. Occasional
uncomplicated left colonic diverticulae +
CT abdomen – for evaluation of bleeding
![Page 7: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/7.jpg)
NON CONTRAST CT
![Page 8: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/8.jpg)
CT : ARTERIAL PHASE
![Page 9: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/9.jpg)
CT: PORTAL VENOUS PHASE
![Page 10: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/10.jpg)
CT: EQUILIBRIUM PHASE
![Page 11: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/11.jpg)
![Page 12: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/12.jpg)
DDs for liver SOL
Can you characterise liver lesions on imaging?
![Page 13: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/13.jpg)
IMAGING OF HEPATOMAS
USG, CT, MRI
![Page 14: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/14.jpg)
ULTRASONOGRAPHY IN HEPATOMA
![Page 15: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/15.jpg)
CT OF HEPATOMA
![Page 16: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/16.jpg)
VALUE OF MRI IN HEPATOMASIDEROTIC NODULE – appears black
Dyplastic nodule:
NO ARTERIAL PHASE ENHANCEMENT
HEPATOMA: ARTERIAL PHASE ENHANCEMENT
![Page 17: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/17.jpg)
Differentiation from other solid liver lesions
Focal Nodular Hyperplasia
![Page 18: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/18.jpg)
HepaticAdenoma
Sub capsular feeding artery
Thin capsule with delayed enhancement.
![Page 19: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/19.jpg)
Hemangioma
![Page 20: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/20.jpg)
Further Evaluation ?
Tumour markers
AFP – 423 IU/dl
DCP/CEA/CA 19 9 - normal
?Biopsy
Decision on curative treatment
![Page 21: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/21.jpg)
Biopsy – to do or not to do!!!!!
Risk of biopsy in liver tumors:
False negative – targetting error
Bleeding
Intrahepatic dissemination
Peritoneal dissemination
When to biopsy??
Resectable lesion – NO BIOPSY
Typical radiological features +/- raised AFP – NO BIOPSY
Atypical radiological features + raised AFP – NO BIOPSY
Atypical radiological features + normal AFP + nonresectable - BIOPSY
![Page 22: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/22.jpg)
How to manage this case ?
Diagnosis conformed by Imaging and AFP
![Page 23: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/23.jpg)
Treatment Options for HCC
Surgical ResectionOpenLaparoscopic
Liver Transplantation
Local Ablative TherapiesRFAPEIMicrowave etc
Regional TherapyTACETheraspheres
Hepatic arterial infusion
Systemic chemotherapyRadiation therapyCyberknife
Multimodality therapy
![Page 24: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/24.jpg)
Treatment of HCC
![Page 25: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/25.jpg)
Performance statusAssociated Medical Diseases
Stage of DiseaseSize /Number of lesions
Extrahepatic diseasePortal vein status
Functional hepatic reserve
Which patients should undergo resection?
![Page 26: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/26.jpg)
What resection and how much to
resect
![Page 27: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/27.jpg)
![Page 28: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/28.jpg)
![Page 29: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/29.jpg)
![Page 30: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/30.jpg)
HCC- Child’s A Cirrhosis
![Page 31: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/31.jpg)
Radiological Assessment?
Virtual Surgery
Volumetry of the Liver to assess for
residual liver or future liver remnant (FLR)
![Page 32: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/32.jpg)
HOW CAN TECHNOLOGY
HELP ?
ADVANCED CT IMAGING TECHNIQUES.
![Page 33: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/33.jpg)
![Page 34: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/34.jpg)
TOTAL LIVER VOLUME: 1256 CC
RESIDUAL LIVER VOLUME: 1256-
440CC = 816CC
PERCENTAGE
RESIDUAL LIVER
VOLUME = 64%
![Page 35: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/35.jpg)
TOTAL LIVER VOLUME: 1256 CC
TUMOR VOLUME = 220 CC
TOTAL FUNCTIONAL LIVER VOLUME = 1256-220:
1036 CC
RESIDUAL LIVER VOLUME: 1036-440 = 596 CC.
PERCENTAGE RESIDUAL
LIVER VOLUME =
596 / 1036 : 57%
![Page 36: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/36.jpg)
Assessment
Patient – Good performance status, fit for surgery; medical
factors well controlled
Disease related – Localised disease; no evidence of spread
Liver Status –rt Posterior sectionectomy, Segment 6,7; Good
residual volume
Facilities – Intraoperative USG; Dissecting tools – Waterjet;
Hemostatic tools – harmonic and Aquamantys
Surgeon and team
![Page 37: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/37.jpg)
Armamentarium
![Page 38: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/38.jpg)
![Page 39: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/39.jpg)
Right post sectionectomy for this
patient
![Page 40: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/40.jpg)
Post operative Course
No major morbidity
Discharged on Day 6
Follow up- doing well
![Page 41: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/41.jpg)
FNAC OR BIOPSY FOR DIAGNOSIS?
Malignant tumours of liver can be confidently
diagnosed on FNAC. However, FNAC has limitations
and diagnostic challenges in benign lesions and well-
differentiated HCC.
Biopsy allows architectural, cellular and
immunohistochemical evaluation.
A combined approach of biopsy with clinical findings,
tumour markers and ancillary techniques is preferred.
![Page 42: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/42.jpg)
Microscopy
MICROACINAR PATTERN
HYALINE GLOBULES WITH POORLY
DIFFERENTIATED CELLS
![Page 43: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/43.jpg)
Results of Biopsy in Suspected HCC
Sensitivity of FNA 67-100%
Specificity of FNA 80-100%
Risk of needle track seeding 2.7% overall, 0.9%/year
Median time for seeding: 17/12 (3-48/12)
Silva MA et al.Gut 2008;57:1592-1596
![Page 44: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/44.jpg)
Pathology of HCC
Histopathology of this patient
Prognostic factors
![Page 45: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/45.jpg)
Histology of HCC
Well-differentiated HCCs are those where the tumour
cells closely resemble hepatocytes.
Poorly differentiated HCC are those where the
hepatocellular nature of the tumour is not
very evident from the morphology.
![Page 46: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/46.jpg)
CORE DATA ITEMS IN PATHOLOGY REPORT
Size
Number
Grade
Vascular invasion
Capsular invasion
Resection margin
Type (fibrolamellar variant better prognosis)
Background liver
Lymph node status
![Page 47: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/47.jpg)
Outcome of Surgery
Good risk patient(Non Cirrhotic, Child A CLD)
Disease Status
Surgical expertise
Strict intra op measures – monitoring, less blood loss
Good residual liver volume
Complete resection with good margin
Favourable pathology
![Page 48: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/48.jpg)
Take home messages
HCC - increasing diagnosis due to awareness
Should be evaluated by an experienced team –to select
the best treatment option for increased chance of cure
Do not needle all liver lesions!
Age and size of tumour really do not necessarily rule out
curative surgery
A meticulously planned surgery with intraoperative and
perioperative care results in excellent outcome
Treatment should be undertaken at center’s with
experience and facilities
![Page 49: Grish hcc presentation](https://reader031.vdocuments.site/reader031/viewer/2022020207/559860161a28ab494e8b462c/html5/thumbnails/49.jpg)
THANK YOU